Serum uric acid levels nor MBD markers were significantly different between the groups at baseline except for FGF-23, which was quantitatively lower in the group randomized to allopurinol compared to placebo (p value = 0.002). This evidence concerns the gene FGF23 and Marchiafava-Bignami disease.